Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.71 -0.49 (-2.22%)
Streaming Delayed Price Updated: 1:30 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
News headline image
Smart Money Is Betting Big In SRPT Options ↗
 
Via Benzinga
News headline image
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript ↗
SRPT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
NASDAQ:SRPT may be ready to breakout. ↗
NASDAQ:SRPT may be ready to breakout. 
Via Chartmill
News headline image
26 Analysts Have This To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
3 Genomics Stocks That May Transform Personalized Medicine ↗
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts ↗
 
Via Benzinga
News headline image
Looking At Sarepta Therapeutics's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know. ↗
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
Via InvestorPlace
News headline image
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
News headline image
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
After a Big Win, Is Sarepta Therapeutics Stock a Buy? ↗
One key issue remains unresolved, and it could be a significant one. 
Via The Motley Fool
News headline image
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? ↗
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. 
Via The Motley Fool
News headline image
1 Soaring Growth Stock to Buy and Hold for 10 Years ↗
Let's look beyond the biotech's performance this year. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. ↗
One company's negative results can increase scrutiny of another's work. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval ↗
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
Via Investor's Business Daily
News headline image
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio? ↗
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
News headline image
Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More ↗
Alphabet stock has more than doubled since February 2023 and it continues to outperform. It boasts a best-possible 99 Composite Rating. 
Via Investor's Business Daily
News headline image
Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year ↗
Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to less impressive performance and subdued earnings expectations. Growth... 
Via Benzinga
News headline image
Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings ↗
 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.